These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 27561921)

  • 21. Clinical impact of initiating insulin glargine therapy with disposable pen versus vial in patients with type 2 diabetes mellitus in a managed care setting.
    Davis SN; Wei W; Garg S
    Endocr Pract; 2011; 17(6):845-52. PubMed ID: 21550952
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Weight change in diabetes and glycemic and blood pressure control.
    Feldstein AC; Nichols GA; Smith DH; Stevens VJ; Bachman K; Rosales AG; Perrin N
    Diabetes Care; 2008 Oct; 31(10):1960-5. PubMed ID: 18697899
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects on Diabetes Medications, Weight and Glycated Hemoglobin Among Adult Patients With Obesity and Type 2 Diabetes: 6-Month Observations From a Full Meal Replacement, Low-Calorie Diet Weight Management Program.
    Shiau JY; So DYF; Dent RR
    Can J Diabetes; 2018 Feb; 42(1):56-60. PubMed ID: 28600119
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland.
    Brändle M; Azoulay M; Greiner RA
    Int J Clin Pharmacol Ther; 2007 Apr; 45(4):203-20. PubMed ID: 17474539
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Results of a Digital Diabetes Self-Management and Education Support Program Among Adults With Type 2 Diabetes: A Retrospective Cohort Study.
    Berthoumieux A; Linke S; Merry M; Megliola A; Juusola J; Napoleone J
    Sci Diabetes Self Manag Care; 2024 Feb; 50(1):19-31. PubMed ID: 38240247
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens.
    Xie L; Wei W; Pan C; Du J; Baser O
    Adv Ther; 2011 Nov; 28(11):1000-11. PubMed ID: 22038703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical predictors of disease progression and medication initiation in untreated patients with type 2 diabetes and A1C less than 7%.
    Pani LN; Nathan DM; Grant RW
    Diabetes Care; 2008 Mar; 31(3):386-90. PubMed ID: 18083790
    [TBL] [Abstract][Full Text] [Related]  

  • 28. INSULIN GLARGINE 300 U/ML IS ASSOCIATED WITH LESS WEIGHT GAIN WHILE MAINTAINING GLYCEMIC CONTROL AND LOW RISK OF HYPOGLYCEMIA COMPARED WITH INSULIN GLARGINE 100 U/ML IN AN AGING POPULATION WITH TYPE 2 DIABETES.
    Munshi MN; Gill J; Chao J; Nikonova EV; Patel M
    Endocr Pract; 2018 Feb; 24(2):143-149. PubMed ID: 29106816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Cost-effectiveness of Two GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus in the Italian Setting: Liraglutide Versus Lixisenatide.
    Hunt B; Kragh N; McConnachie CC; Valentine WJ; Rossi MC; Montagnoli R
    Clin Ther; 2017 Jul; 39(7):1347-1359. PubMed ID: 28625506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of exenatide versus insulin analogues on weight change in subjects with type 2 diabetes: a pooled post-hoc analysis.
    Glass LC; Qu Y; Lenox S; Kim D; Gates JR; Brodows R; Trautmann M; Bergenstal RM
    Curr Med Res Opin; 2008 Mar; 24(3):639-44. PubMed ID: 18218179
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quality measure attainment in patients with type 2 diabetes mellitus.
    Lafeuille MH; Grittner AM; Gravel J; Bailey RA; Martin S; Garber L; Sheng Duh M; Lefebvre P
    Am J Manag Care; 2014 Jan; 20(1 Suppl):s5-15. PubMed ID: 24512194
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weight change and healthcare resource use in English patients with type 2 diabetes mellitus initiating a new diabetes medication class.
    Blak BT; Rigney U; Sternhufvud C; Davis J; Hammar N
    Int J Clin Pract; 2016 Jan; 70(1):45-55. PubMed ID: 26620492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Longitudinal follow up of dysglycemia in overweight and obese pediatric patients.
    Love-Osborne KA; Sheeder JL; Nadeau KJ; Zeitler P
    Pediatr Diabetes; 2018 Mar; 19(2):199-204. PubMed ID: 28856775
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Impact of rosiglitazone therapy on the lipid profile, glycemic control, and medication costs among type 2 diabetes patients.
    Suh DC; Lee DH; McGuire M; Kim CM
    Curr Med Res Opin; 2011 Aug; 27(8):1623-33. PubMed ID: 21696266
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of weight gain on medical care costs.
    Elmer PJ; Brown JB; Nichols GA; Oster G
    Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1365-73. PubMed ID: 15356665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics associated with maintenance of mean A1C<6.5% in people with dysglycemia in the ORIGIN trial.
    ORIGIN Trial Investigators
    Diabetes Care; 2013 Oct; 36(10):2915-22. PubMed ID: 23656980
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Association between glycemic control and short-term healthcare costs among commercially insured diabetes patients in the United States.
    Aagren M; Luo W
    J Med Econ; 2011; 14(1):108-14. PubMed ID: 21241161
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Healthcare costs associated with change in body mass index in patients with type 2 diabetes mellitus in Spain: the ECOBIM study.
    Dilla T; Valladares A; Nicolay C; Salvador J; Reviriego J; Costi M
    Appl Health Econ Health Policy; 2012 Nov; 10(6):417-30. PubMed ID: 23013427
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining predictors of response to exenatide in type 2 diabetes.
    Anderson SL; Trujillo JM; McDermott M; Saseen JJ
    J Am Pharm Assoc (2003); 2012; 52(4):466-71. PubMed ID: 22825226
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Relationship of hemoglobin A1c, age of diabetes diagnosis, and ethnicity to clinical outcomes and medical costs in a computer-simulated cohort of persons with type 2 diabetes.
    de Lissovoy G; Ganoczy DA; Ray NF
    Am J Manag Care; 2000 May; 6(5):573-84. PubMed ID: 10977465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.